FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225974045> ?p ?o ?g. }

• W4225974045 abstract "Coronaviruses are a major health care threat to humankind. Currently, the host factors that contribute to limit disease severity in healthy young patients are not well defined. Interferons are key antiviral molecules, especially type I and type III interferons. The role of these interferons during coronavirus disease is a subject of debate. Here, using mice that are deficient in type I (IFNAR1-/-), type III (IFNLR1-/-), or both (IFNAR1/LR1-/-) interferon signaling pathways and murine-adapted coronavirus (MHV-A59) administered through the intranasal route, we define the role of interferons in coronavirus infection. We show that type I interferons play a major role in host survival in this model, while a minimal role of type III interferons was manifested only in the absence of type I interferons or during a lethal dose of coronavirus. IFNAR1-/- and IFNAR1/LR1-/- mice had an uncontrolled viral burden in the airways and lung and increased viral dissemination to other organs. The absence of only type III interferon signaling had no measurable difference in the viral load. The increased viral load in IFNAR1-/- and IFNAR1/LR1-/- mice was associated with increased tissue injury, especially evident in the lung and liver. Type I but not type III interferon treatment was able to promote survival if treated during early disease. Further, we show that type I interferon signaling in macrophages contributes to the beneficial effects during coronavirus infection in mice. IMPORTANCE The antiviral and pathological potential of type I and type III interferons during coronavirus infection remains poorly defined, and opposite findings have been reported. We report that both type I and type III interferons have anticoronaviral activities, but their potency and organ specificity differ. Type I interferon deficiency rendered the mice susceptible to even a sublethal murine coronavirus infection, while the type III interferon deficiency impaired survival only during a lethal infection or during a sublethal infection in the absence of type I interferon signaling. While treatment with both type I and III interferons promoted viral clearance in the airways and lung, only type I interferons promoted the viral clearance in the liver and improved host survival upon early treatment (12 h postinfection). This study demonstrates distinct roles and potency of type I and type III interferons and their therapeutic potential during coronavirus lung infection." @default.
• W4225974045 created "2022-05-05" @default.
• W4225974045 creator A5002693861 @default.
• W4225974045 creator A5002746422 @default.
• W4225974045 creator A5003399137 @default.
• W4225974045 creator A5007098015 @default.
• W4225974045 creator A5016891336 @default.
• W4225974045 creator A5018699102 @default.
• W4225974045 creator A5024994715 @default.
• W4225974045 creator A5026315981 @default.
• W4225974045 creator A5036635642 @default.
• W4225974045 creator A5037631027 @default.
• W4225974045 creator A5051847894 @default.
• W4225974045 creator A5053023377 @default.
• W4225974045 creator A5053275663 @default.
• W4225974045 creator A5054446792 @default.
• W4225974045 creator A5056625739 @default.
• W4225974045 creator A5057589025 @default.
• W4225974045 creator A5064251681 @default.
• W4225974045 creator A5064337022 @default.
• W4225974045 creator A5068078572 @default.
• W4225974045 creator A5080746544 @default.
• W4225974045 creator A5083333758 @default.
• W4225974045 creator A5083411426 @default.
• W4225974045 creator A5086324123 @default.
• W4225974045 creator A5087257594 @default.
• W4225974045 date "2022-01-26" @default.
• W4225974045 modified "2023-10-11" @default.
• W4225974045 title "Distinct Roles of Type I and Type III Interferons during a Native Murine β Coronavirus Lung Infection" @default.
• W4225974045 cites W1488854843 @default.
• W4225974045 cites W2013202475 @default.
• W4225974045 cites W2055968512 @default.
• W4225974045 cites W2062414933 @default.
• W4225974045 cites W2079295092 @default.
• W4225974045 cites W2079771032 @default.
• W4225974045 cites W2086891794 @default.
• W4225974045 cites W2110812524 @default.
• W4225974045 cites W2127064732 @default.
• W4225974045 cites W2147073267 @default.
• W4225974045 cites W2160063406 @default.
• W4225974045 cites W2517728041 @default.
• W4225974045 cites W2597176252 @default.
• W4225974045 cites W2605389562 @default.
• W4225974045 cites W2616524644 @default.
• W4225974045 cites W2808687381 @default.
• W4225974045 cites W2886436228 @default.
• W4225974045 cites W2936804536 @default.
• W4225974045 cites W3004824173 @default.
• W4225974045 cites W3005347918 @default.
• W4225974045 cites W3010538497 @default.
• W4225974045 cites W3012610905 @default.
• W4225974045 cites W3014067025 @default.
• W4225974045 cites W3016785135 @default.
• W4225974045 cites W3020062806 @default.
• W4225974045 cites W3022536911 @default.
• W4225974045 cites W3025395896 @default.
• W4225974045 cites W3034873991 @default.
• W4225974045 cites W3035343971 @default.
• W4225974045 cites W3036536710 @default.
• W4225974045 cites W3041960835 @default.
• W4225974045 cites W3042829909 @default.
• W4225974045 cites W3043831218 @default.
• W4225974045 cites W3046988613 @default.
• W4225974045 cites W305471496 @default.
• W4225974045 cites W3081073771 @default.
• W4225974045 cites W3081787674 @default.
• W4225974045 cites W3082568883 @default.
• W4225974045 cites W3087207483 @default.
• W4225974045 cites W3094171379 @default.
• W4225974045 cites W3107191813 @default.
• W4225974045 cites W3109840215 @default.
• W4225974045 cites W3119294241 @default.
• W4225974045 cites W3128393910 @default.
• W4225974045 cites W3133105869 @default.
• W4225974045 cites W3142091149 @default.
• W4225974045 cites W3165656738 @default.
• W4225974045 cites W3191057636 @default.
• W4225974045 cites W4233800959 @default.
• W4225974045 doi "https://doi.org/10.1128/jvi.01241-21" @default.
• W4225974045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34705554" @default.
• W4225974045 hasPublicationYear "2022" @default.
• W4225974045 type Work @default.
• W4225974045 citedByCount "6" @default.
• W4225974045 countsByYear W42259740452022 @default.
• W4225974045 countsByYear W42259740452023 @default.
• W4225974045 crossrefType "journal-article" @default.
• W4225974045 hasAuthorship W4225974045A5002693861 @default.
• W4225974045 hasAuthorship W4225974045A5002746422 @default.
• W4225974045 hasAuthorship W4225974045A5003399137 @default.
• W4225974045 hasAuthorship W4225974045A5007098015 @default.
• W4225974045 hasAuthorship W4225974045A5016891336 @default.
• W4225974045 hasAuthorship W4225974045A5018699102 @default.
• W4225974045 hasAuthorship W4225974045A5024994715 @default.
• W4225974045 hasAuthorship W4225974045A5026315981 @default.
• W4225974045 hasAuthorship W4225974045A5036635642 @default.
• W4225974045 hasAuthorship W4225974045A5037631027 @default.
• W4225974045 hasAuthorship W4225974045A5051847894 @default.
• W4225974045 hasAuthorship W4225974045A5053023377 @default.
• W4225974045 hasAuthorship W4225974045A5053275663 @default.
• W4225974045 hasAuthorship W4225974045A5054446792 @default.

• next